Skip to Content
Merck
CN
All Photos(1)

Documents

MAB8878

Sigma-Aldrich

Anti-Cdk1 Antibody, clone A17.1.1

clone A17.1.1, Chemicon®, from mouse

Sign Into View Organizational & Contract Pricing

Synonym(s):
p34cdc2, CDC2
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41

biological source

mouse

Quality Level

antibody form

purified immunoglobulin

antibody product type

primary antibodies

clone

A17.1.1, monoclonal

species reactivity

human, Xenopus, mouse, rat, chicken

manufacturer/tradename

Chemicon®

technique(s)

activity assay: suitable
immunofluorescence: suitable
immunohistochemistry: suitable (paraffin)
immunoprecipitation (IP): suitable
western blot: suitable

isotype

IgG2a

NCBI accession no.

UniProt accession no.

shipped in

wet ice

target post-translational modification

unmodified

Gene Information

mouse ... Cdk1(12534)

Specificity

Recognizes a 34 kDa protein cdk1, identified as cdk1/p34cdc2 protein kinase (a catalytic subunit of Maturation Promoting Factor). Its epitope maps near the C-terminus of protein and its core is thought to be LGTPNNEV. It shows no cross-reaction with cdk2/p32 and other cyclin dependent kinases (cdks).

Immunogen

Raised against Xenopus p34cdc2.

Application

Anti-Cdk1 Antibody, clone A17.1.1 is a Mouse Monoclonal Antibody for detection of Cdk1 also known as p34cdc2, CDC2 & has been validated in IF, IP, EA, WB, IHC(P).
Frozen Sections

Immunofluorescence

Immunoprecipitation: (Native/denatured, Protein A; 2μg/mg protein lysate)

Immunohistology (Formalin, 2-4μg/mL for 30 min at RT)

Paraffin Sections (staining requires antigen retrieval).

Western Blotting

Kinase Assay

Optimal working dilutions must be determined by the end user.

p34cdc2, a serine/threonine kinase, is activated by cyclins, presumably by dephosphorylation of tyrosine residues. MAB8878 inhibits the activation of p34cdc2 kinase by cyclins and precipitates an active kinase.
Research Category
Epigenetics & Nuclear Function
Research Sub Category
Cell Cycle, DNA Replication & Repair

Physical form

Format: Purified
Purified immunoglobulin. 0.2 mg/mL in 10 mM PBS, pH 7.4, containing 0.2% BSA and 0.09% Sodium Azide.

Storage and Stability

Maintain at 2° to 8°C in undiluted aliquots for up to 12 months from date of receipt.

Analysis Note

Control
POSITIVE CONTROL:

HeLa or NIH3T3 cells. Germinal center in a tonsil or reactive lymph node. Cellular localization is predominantly nuclear, with some cytoplasmic staining.

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Legal Information

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Ian M McDonald et al.
The Journal of biological chemistry, 295(8), 2359-2374 (2020-01-04)
The maternal embryonic leucine zipper kinase (MELK) has been implicated in the regulation of cancer cell proliferation. RNAi-mediated MELK depletion impairs growth and causes G2/M arrest in numerous cancers, but the mechanisms underlying these effects are poorly understood. Furthermore, the
E M Alexandrova et al.
Nature, 523(7560), 352-356 (2015-05-27)
Missense mutations in p53 generate aberrant proteins with abrogated tumour suppressor functions that can also acquire oncogenic gain-of-function activities that promote malignant progression, invasion, metastasis and chemoresistance. Mutant p53 (mutp53) proteins undergo massive constitutive stabilization specifically in tumours, which is
Aisling Pierce et al.
Cancer biology & therapy, 14(6), 537-545 (2013-06-14)
PARP inhibitors, both as monotherapy and in combination with cytotoxic drugs, are currently undergoing clinical trials in several different cancer types. In this investigation, we compared the antiproliferative activity of two PARP/putative PARP inhibitors, i.e., olaparib and iniparib, in a
Lucía San Juan et al.
Cell death discovery, 9(1), 21-21 (2023-01-22)
Epithelial transdifferentiation is frequent in tissue hyperplasia and contributes to disease in various degrees. Squamous metaplasia (SQM) precedes epidermoid lung cancer, an aggressive and frequent malignancy, but it is rare in the epithelium of the mammary gland. The mechanisms leading
Stephen Gray et al.
Cell reports, 32(1), 107858-107858 (2020-07-09)
During mammalian meiotic prophase I, programmed DNA double-strand breaks are repaired by non-crossover or crossover events, the latter predominantly occurring via the class I crossover pathway and requiring the cyclin N-terminal domain-containing 1(CNTD1) protein. Using an epitope-tagged Cntd1 allele, we

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service